PMID- 9108438
OWN - NLM
STAT- MEDLINE
DCOM- 19970501
LR  - 20181130
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 57
IP  - 8
DP  - 1997 Apr 15
TI  - A naturally occurring mutant human epidermal growth factor receptor as a target 
      for peptide vaccine immunotherapy of tumors.
PG  - 1419-24
AB  - The type III EGF receptor (EGFRvIII) is the result of an in-frame deletion from 
      nucleotides 275 to 1075 in the EGF receptor cDNA sequence creating a novel 
      epitope at the fusion junction. This spontaneously occurring alteration is found 
      in a high percentage of primary human brain, breast, lung and ovarian tumors. We 
      have explored whether a peptide derived from the fusion junction could serve as 
      the basis for an antitumor vaccine. Preimmunization of mice with this peptide 
      substantially inhibited tumor formation by cells expressing EGFRvIII. Tumor cell 
      inoculation followed by immunization could also enhance the regression of 
      existing tumors. Antibody production was elicited in animals that was highly 
      specific for the novel epitope and also a CTL response that was mediated by CD8+ 
      T lymphocytes. The alteration present in EGFRvIII could serve as the basis for an 
      antitumor vaccine with potentially wide application in humans.
FAU - Moscatello, D K
AU  - Moscatello DK
AD  - Department of Microbiology and Immunology, Kimmel Cancer Institute, Thomas 
      Jefferson University, Philadelphia, Pennsylvania 19107, USA.
FAU - Ramirez, G
AU  - Ramirez G
FAU - Wong, A J
AU  - Wong AJ
LA  - eng
GR  - 5T32-CA09678/CA/NCI NIH HHS/United States
GR  - CA-51093/CA/NCI NIH HHS/United States
GR  - CA-69495/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (Cancer Vaccines)
RN  - 0 (DNA, Complementary)
RN  - 0 (Epitopes)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - 3T3 Cells
MH  - Animals
MH  - Cancer Vaccines/immunology/*therapeutic use
MH  - DNA, Complementary/*genetics
MH  - Epitopes/*immunology
MH  - ErbB Receptors/classification/genetics/*immunology
MH  - Female
MH  - Humans
MH  - *Immunotherapy
MH  - Mice
MH  - Neoplasms, Experimental/genetics/immunology/*therapy
MH  - Rats
MH  - Rats, Inbred F344
MH  - *Sequence Deletion
MH  - T-Lymphocytes, Cytotoxic/*immunology
MH  - Transfection
EDAT- 1997/04/15 00:00
MHDA- 1997/04/15 00:01
CRDT- 1997/04/15 00:00
PHST- 1997/04/15 00:00 [pubmed]
PHST- 1997/04/15 00:01 [medline]
PHST- 1997/04/15 00:00 [entrez]
PST - ppublish
SO  - Cancer Res. 1997 Apr 15;57(8):1419-24.